[Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia].
In spite of various cause of hyperphosphatemia, there is a limited number of modality which include restriction of phosphate intake, phosphate binder, extra cellular fluid expansion and blood purification. Each therapy has certain deficit but combination of those may get preferable consequence. Now various new phosphate binders and the inhibitors of sodium-dependent phosphate transporters are being developed. Those agents might promise a better outcome of the treatment of hyperphosphatemia.
Skaguchi
Toshifumi
T
Division of Nephrology and Blood Purification, Wakayama Medical University.
Shigematsu
Takashi
T
D000085:Acetates / Q000627:therapeutic use; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D002119:Calcium Carbonate / Q000627:therapeutic use; D017610:Calcium Compounds / Q000627:therapeutic use; D002614:Chelating Agents / Q000627:therapeutic use; D015195:Drug Design; D005782:Gels; D006801:Humans; D054559:Hyperphosphatemia / Q000209:etiology* / Q000628:therapy*; D007811:Lanthanum / Q000627:therapeutic use; D046911:Macromolecular Substances; D016226:Phosphorus, Dietary / Q000008:administration & dosage; D011073:Polyamines / Q000627:therapeutic use; D011108:Polymers; D006435:Renal Dialysis; D000069603:Sevelamer
D000085:Acetates; D017610:Calcium Compounds; D002614:Chelating Agents; D005782:Gels; D046911:Macromolecular Substances; D016226:Phosphorus, Dietary; D011073:Polyamines; D011108:Polymers; C119467:lanthanum carbonate; D000536:Aluminum Hydroxide; D007811:Lanthanum; D000069603:Sevelamer; D002119:Calcium Carbonate; C120662:calcium acetate